Publications by authors named "Perihan Perkin"
Purpose: Cancer caregiving presents significant psychological and emotional challenges. While healthcare workers (HCWs) possess medical expertise, their dual role as both professionals and caregivers may impose additional burdens. This study examines the psychological distress and caregiving burden among HCWs and non-HCWs caring for oncology patients.
View Article and Find Full Text PDFReal‑world efficacy and safety data of immune checkpoint inhibitors in Turkish patients with metastatic melanoma: A Turkish oncology group retrospective study.
Mol Clin Oncol
June 2025
In recent years, significant success has been achieved in the treatment of metastatic melanoma with the use of immune checkpoint inhibitors (ICIs), and it resulted in a remarkable increase in patient survival. However, there are only a few studies reflecting daily practice outside of clinical trials. The present study aimed to evaluate the effectiveness and safety of ICI therapy in Turkish patients with metastatic melanoma, including those with poor prognostic factors such as advanced age and brain metastasis.
View Article and Find Full Text PDFIntroduction: Biliary tract cancers (BTC) comprise a heterogeneous group of malignancies, including gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. The main determinants of prognosis in BTC are the stage of the disease and the eligibility for curative treatment. Additionally, liver functional capacity is also one of the factors influencing survival in biliary tract cancers.
View Article and Find Full Text PDFImmune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but are associated with immune-related adverse events (irAEs). Pembrolizumab, an anti-PD-1 antibody, is widely used in non-small cell lung cancer (NSCLC), yet immune thrombocytopenia remains a rare but potentially fatal complication. We report a case of a 55-year-old male with metastatic NSCLC who developed pembrolizumab-associated immune thrombocytopenia.
View Article and Find Full Text PDFArticle Synopsis
- Endometrium cancer is the most common gynecological cancer in developed countries, and this study was conducted to assess how HER2 positivity affects patient prognosis.
- The study analyzed 121 patients diagnosed with endometrial cancer between September 2019 and December 2023, categorizing them into HER2-low and HER2-high groups based on their HER2 immunohistochemistry scores.
- Findings showed that those in the HER2-high group had better survival outcomes than those in the HER2-low group, and both FIGO stage and HER2 status emerged as independent risk factors influencing overall survival.
Article Synopsis
- - Letrozole is an aromatase inhibitor used for hormone-positive breast cancer treatment, which lowers estrogen levels by blocking the conversion of androgens to estrogen but may lead to rare side effects, including acute heart failure.
- - A 57-year-old woman developed acute heart failure with a significantly reduced ejection fraction (20%) two weeks after starting letrozole treatment following her breast cancer surgery and radiotherapy.
- - Upon stopping letrozole, the patient showed improvement in heart function, highlighting that heart failure related to letrozole can potentially be reversible, but patients should be monitored for cardiac symptoms.
Article Synopsis
- * This study analyzed the effectiveness of two treatments, pazopanib and sunitinib, in non-ccRCC patients across 22 hospitals, looking at progression-free survival, overall survival, and patient response rates.
- * The findings suggest that pazopanib and sunitinib have similar efficacy, with specific patient characteristics affecting outcomes; pazopanib could be considered a viable treatment option alongside sunitinib and cabozantinib.
Article Synopsis
- Triple negative breast cancer (TNBC) often recurs after treatment, particularly in those with residual disease post-chemotherapy, and capecitabine is commonly used as a follow-up treatment for these patients.! -
- A study analyzed 170 TNBC patients who received capecitabine after neoadjuvant chemotherapy, finding a 30% recurrence rate and 18% death rate, with a 3-year disease-free survival (DFS) of 66% and overall survival (OS) of 74% in the cohort.! -
- Results indicated that while capecitabine's effectiveness was lower than past studies, certain patients, especially those with specific residual disease characteristics, could still benefit from it,
Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study.
J Chemother
February 2025
Article Synopsis
- The MONALEESA-7 study is the only phase 3 research on CDK 4-6 inhibitors for premenopausal patients with hormone receptor-positive, HER2 negative metastatic breast cancer, but there is limited data on palbociclib's effectiveness.
- Our multicenter, retrospective study included 319 patients to evaluate the effectiveness of palbociclib and ribociclib in first-line treatment and how dose reduction due to neutropenia affects progression-free survival (PFS).
- Results showed similar median PFS for both drugs (26.83 months for palbociclib and 29.86 months for ribociclib) and no significant impact of dose reduction on effectiveness, with P
To compare the seropositivity rate of cancer patients with noncancer controls after inactive SARS-CoV-2 vaccination and evaluate the factors affecting seropositivity. Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 noncancer volunteers. An IgG level ≥50 AU/ml is accepted as seropositive.
View Article and Find Full Text PDF